Accelerated Trial definition

Accelerated Trial means a trial which complies with the dispute resolution procedures set forth in Section 17.3.
Sample 1Sample 2Sample 3

Examples of Accelerated Trial in a sentence

  • The exercise of any such right or remedy by a party shall not waive the right of that party to resort to an Accelerated Trial.

  • Landlord, within ten (10) Business Days of receipt of such claim from Tenant, or concurrently with delivery of written notice to Tenant that a dispute exists as to the claim, or such part of it as the notifying party designates, may elect to resolve such dispute by Accelerated Trial pursuant this Section.

  • The parties acknowledge and agree that the provisions of this Section for Accelerated Trial are limited to those certain disputes at the election of Landlord that Landlord expressly agrees would be so resolved.

  • All other disputes between the parties shall be resolved in the manner otherwise available at law or in equity and Accelerated Trial of an issue in the manner set forth in this Section shall not preclude any party from bringing a separate action in any court of competent jurisdiction on a related issue.

  • LR 73-2 Accelerated Trial Scheduling Unlike District Judges who are assigned both civil and criminal cases, and by law must give scheduling priority to criminal cases, Magistrate Judges are assigned civil cases and criminal misdemeanor and petty offense cases only.

  • CourtsCheck all topics covered in policies.a. Accelerated Trial Schedulesb.

  • Any fact or document agreed shall be deemed to have been admitted. Also see The Accelerated Trial and Disposal of Cases Rules, 1988 – GN 192 of 1988. Compliance with every stage of this procedure, particularly subsection (3) of section 192 thereof, is mandatory – Libert Hubertv.

  • Upon a finding of special circumstances, the SpecialMaster shall recommend to the Court for inclusion of a case into the Accelerated Trial Cluster despite a late application.

  • Except upon application to the Special Master for good cause shown, upon application to be included in an Accelerated Trial Cluster, to the extent plaintiff has such records listed in (3) in the previous sentence in its possession it shall produce copies to defendants.

  • However, if the plaintiff is still living at the time the window for next Accelerated Trial Cluster opens, plaintiffmay reapply for inclusion in that cluster if the plaintiff is alive at the time of application.

Related to Accelerated Trial

  • Development Milestone Event has the meaning set forth in Section 7.2.1.

  • muscular dystrophy means a group of hereditary genetic muscle disease that weakens the muscles that move the human body and persons with multiple dystrophy have incorrect and missing information in their genes, which prevents them from making the proteins they need for healthy muscles. It is characterised by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue;

  • Development Milestone is defined in Section 5.3.

  • Project Milestone means the project milestone set forth in Schedule-J;

  • Control Performance Standard or “CPS” shall mean the reliability standard that sets the limits of a Balancing Authority’s Area Control Error over a specified time period.

  • Milestone Event has the meaning set forth in Section 8.2.1.

  • Performance Milestone means an act or event specified in section 5.1 and described in section 9 of the EPLA.

  • Milestone Dates means the dates for completion of specified Project activities as contained in the Project Schedule.

  • Project Milestones means the project milestones set forth in Schedule-G;

  • Development Milestone Payment shall have the meaning set forth in Section 9.2(a).

  • Phase 3 Trial means a human clinical trial of a Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Product, as described in 21 C.F.R. 312.21(c) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.

  • Key Performance Indicator means a measure that captures the performance of a critical variable to expand and improve community-based corrections programs to promote offender success, ensure accountability, enhance public safety, and reduce recidivism.

  • Treatability study means a study in which a hazardous waste is subjected to a treatment process to determine: (1) Whether the waste is amenable to the treatment process, (2) what pretreatment (if any) is required, (3) the optimal process conditions needed to achieve the desired treatment, (4) the efficiency of a treatment process for a specific waste or wastes, or (5) the characteristics and volumes of residuals from a particular treatment process. Also included in this definition for the purpose of the § 261.4 (e) and (f) exemptions are liner compatibility, corrosion, and other material compatibility studies and toxicological and health effects studies. A “treatability study” is not a means to commercially treat or dispose of hazardous waste.

  • Phase II Trial means a clinical trial of a Licensed Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b), or its successor regulation, or the equivalent in any foreign country.

  • Milestone Events has the meaning set forth in Section 7.2.

  • Phase III Trial means a Clinical Trial of an investigational product in subjects that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to generate data and results that can be submitted to obtain Regulatory Approval as described in 21 C.F.R. 312.21(c), or a comparable Clinical Trial prescribed by the relevant Regulatory Authority in a country other than the United States.

  • Corrective Measure means a measure as defined in Article 3, point 16, of Regulation (EU) 2019/1020;

  • Milestone Schedule means Seller’s milestone schedule, the form of which is attached to this Agreement as Exhibit Q.

  • Phase I Trial means a Clinical Trial, the principal purpose of which is preliminary determination of safety of an investigational product in healthy individuals or patients or that otherwise meets the requirements described in 21 C.F.R. §312.21(a), or similar Clinical Trial in a country other than the United States.

  • Phase 2 Trial means a human clinical trial conducted on study subjects with the disease or condition being studied for the principal purpose of achieving a preliminary determination of efficacy or appropriate dosage ranges, as further described in 21 C.F.R. §312.21(b) (including any such clinical study in any country other than the United States).

  • Clinical Trial means any human clinical trial of a Product.

  • Pivotal Study means (a) a Phase 3 Study that is intended by Celgene to be submitted (together with any other registration trials that are prospectively planned when such Phase 3 Study is initiated) for Regulatory Approval in the U.S. or the EU, or (b) any other clinical study that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which clinical study is a registration trial intended to be sufficient for filing an application for a Regulatory Approval for the Licensed Product in the U.S. or another country or some or all of an extra-national territory, solely as evidenced by the acceptance for filing for a Regulatory Approval for such product after completion of such study.

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Performance Standard means the acceptable range of performance for a Performance Indicator or a Service Volume that results when a Performance Corridor is applied to a Performance Target;

  • Additional SDU Study means a deliverability study that a Developer may elect to pursue as that term is defined in OATT Section 25 (OATT Attachment S). For purposes of Section 23.4.5 of this Attachment H, “Affiliated Entity” shall mean, with respect to a person or Entity: